array:21 [
  "pii" => "X0211699512002267"
  "issn" => "02116995"
  "doi" => "10.3265/Nefrologia.pre2012.Jun.11242"
  "estado" => "S300"
  "fechaPublicacion" => "2012-11-01"
  "documento" => "article"
  "licencia" => "http://www.elsevier.com/open-access/userlicense/1.0/"
  "subdocumento" => "fla"
  "cita" => "Nefrologia. 2012;32:790-6"
  "abierto" => array:3 [
    "ES" => true
    "ES2" => true
    "LATM" => true
  ]
  "gratuito" => true
  "lecturas" => array:2 [
    "total" => 12406
    "formatos" => array:3 [
      "EPUB" => 346
      "HTML" => 10789
      "PDF" => 1271
    ]
  ]
  "Traduccion" => array:1 [
    "en" => array:17 [
      "pii" => "X2013251412002264"
      "issn" => "20132514"
      "doi" => "10.3265/Nefrologia.pre2012.Jun.11242"
      "estado" => "S300"
      "fechaPublicacion" => "2012-11-01"
      "documento" => "article"
      "licencia" => "http://www.elsevier.com/open-access/userlicense/1.0/"
      "subdocumento" => "fla"
      "cita" => "Nefrologia (English Version). 2012;32:790-6"
      "abierto" => array:3 [
        "ES" => true
        "ES2" => true
        "LATM" => true
      ]
      "gratuito" => true
      "lecturas" => array:2 [
        "total" => 6654
        "formatos" => array:3 [
          "EPUB" => 295
          "HTML" => 5475
          "PDF" => 884
        ]
      ]
      "en" => array:12 [
        "idiomaDefecto" => true
        "titulo" => "The effect of pentoxifylline on reduction of proteinuria among patients with type 2 diabetes under blockade of angiotensin system: a double blind and randomized clinical trial"
        "tienePdf" => "en"
        "tieneTextoCompleto" => "en"
        "tieneResumen" => array:2 [
          0 => "es"
          1 => "en"
        ]
        "paginas" => array:1 [
          0 => array:2 [
            "paginaInicial" => "790"
            "paginaFinal" => "796"
          ]
        ]
        "titulosAlternativos" => array:1 [
          "es" => array:1 [
            "titulo" => "El efecto de la pentoxifilina en la reducción de proteinuria en pacientes con diabetes tipo 2 con bloqueo del sistema de angiotensina: ensayo clínico doble ciego y aleatorizado"
          ]
        ]
        "contieneResumen" => array:2 [
          "es" => true
          "en" => true
        ]
        "contieneTextoCompleto" => array:1 [
          "en" => true
        ]
        "contienePdf" => array:1 [
          "en" => true
        ]
        "resumenGrafico" => array:2 [
          "original" => 0
          "multimedia" => array:8 [
            "identificador" => "fig1"
            "etiqueta" => "Tab.  1"
            "tipo" => "MULTIMEDIAFIGURA"
            "mostrarFloat" => true
            "mostrarDisplay" => false
            "copyright" => "Elsevier España"
            "figura" => array:1 [
              0 => array:4 [
                "imagen" => "11242_16025_23451_en_t111242.jpg"
                "Alto" => 639
                "Ancho" => 2180
                "Tamanyo" => 413272
              ]
            ]
            "descripcion" => array:1 [
              "en" => "Baseline demographic and clinical characteristics of patients"
            ]
          ]
        ]
        "autores" => array:1 [
          0 => array:2 [
            "autoresLista" => "Ali Ghorbani, Bita Omidvar, Seyed S. Beladi-Mousavi, Seyed Seifollah Beladi Mousavi, Elena Lak, Sima Vaziri"
            "autores" => array:10 [
              0 => array:2 [
                "nombre" => "Ali"
                "apellidos" => "Ghorbani"
              ]
              1 => array:2 [
                "nombre" => "Ali"
                "apellidos" => "Ghorbani"
              ]
              2 => array:2 [
                "nombre" => "Bita"
                "apellidos" => "Omidvar"
              ]
              3 => array:2 [
                "nombre" => "Bita"
                "apellidos" => "Omidvar"
              ]
              4 => array:2 [
                "nombre" => "Seyed S."
                "apellidos" => "Beladi-Mousavi"
              ]
              5 => array:2 [
                "nombre" => "Seyed Seifollah"
                "apellidos" => "Beladi Mousavi"
              ]
              6 => array:2 [
                "nombre" => "Elena"
                "apellidos" => "Lak"
              ]
              7 => array:2 [
                "nombre" => "Elena"
                "apellidos" => "Lak"
              ]
              8 => array:2 [
                "nombre" => "Sima"
                "apellidos" => "Vaziri"
              ]
              9 => array:2 [
                "nombre" => "Sima"
                "apellidos" => "Vaziri"
              ]
            ]
          ]
        ]
      ]
      "idiomaDefecto" => "en"
      "Traduccion" => array:1 [
        "es" => array:9 [
          "pii" => "X0211699512002267"
          "doi" => "10.3265/Nefrologia.pre2012.Jun.11242"
          "estado" => "S300"
          "subdocumento" => ""
          "abierto" => array:3 [
            "ES" => true
            "ES2" => true
            "LATM" => true
          ]
          "gratuito" => true
          "lecturas" => array:1 [
            "total" => 0
          ]
          "idiomaDefecto" => "es"
          "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X0211699512002267?idApp=UINPBA000064"
        ]
      ]
      "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X2013251412002264?idApp=UINPBA000064"
      "url" => "/20132514/0000003200000006/v0_201502091602/X2013251412002264/v0_201502091603/en/main.assets"
    ]
  ]
  "itemSiguiente" => array:17 [
    "pii" => "X0211699512002259"
    "issn" => "02116995"
    "doi" => "10.3265/Nefrologia.pre2012.Sep.11367"
    "estado" => "S300"
    "fechaPublicacion" => "2012-11-01"
    "documento" => "article"
    "licencia" => "http://www.elsevier.com/open-access/userlicense/1.0/"
    "subdocumento" => "fla"
    "cita" => "Nefrologia. 2012;32:797-808"
    "abierto" => array:3 [
      "ES" => true
      "ES2" => true
      "LATM" => true
    ]
    "gratuito" => true
    "lecturas" => array:2 [
      "total" => 8733
      "formatos" => array:3 [
        "EPUB" => 313
        "HTML" => 7759
        "PDF" => 661
      ]
    ]
    "es" => array:12 [
      "idiomaDefecto" => true
      "titulo" => "Conocimiento y aplicación en la práctica real del Documento de consenso S.E.N.-semFYC sobre la enfermedad renal crónica"
      "tienePdf" => "es"
      "tieneTextoCompleto" => "es"
      "tieneResumen" => array:2 [
        0 => "es"
        1 => "en"
      ]
      "paginas" => array:1 [
        0 => array:2 [
          "paginaInicial" => "797"
          "paginaFinal" => "808"
        ]
      ]
      "titulosAlternativos" => array:1 [
        "en" => array:1 [
          "titulo" => "Awareness and implementation in daily practice of the S.E.N.-semFYC consensus document on chronic kidney disease"
        ]
      ]
      "contieneResumen" => array:2 [
        "es" => true
        "en" => true
      ]
      "contieneTextoCompleto" => array:1 [
        "es" => true
      ]
      "contienePdf" => array:1 [
        "es" => true
      ]
      "resumenGrafico" => array:2 [
        "original" => 0
        "multimedia" => array:8 [
          "identificador" => "fig1"
          "etiqueta" => "Tab.  1"
          "tipo" => "MULTIMEDIAFIGURA"
          "mostrarFloat" => true
          "mostrarDisplay" => false
          "copyright" => "Elsevier España"
          "figura" => array:1 [
            0 => array:4 [
              "imagen" => "11367_19759_26453_es_11367_t1.jpg"
              "Alto" => 738
              "Ancho" => 600
              "Tamanyo" => 570988
            ]
          ]
          "descripcion" => array:1 [
            "es" => "Texto de las recomendaciones de contexto evaluadas en el estudio"
          ]
        ]
      ]
      "autores" => array:1 [
        0 => array:2 [
          "autoresLista" => "M. Isabel Egocheaga, Roberto Alcázar, José M. Lobos, J. Luis Górriz, Alberto Martínez-Castelao, Ana Pastor, Isabel Martínez, Fernando Caballero, Marta Sánchez-Celaya"
          "autores" => array:9 [
            0 => array:2 [
              "nombre" => "M. Isabel"
              "apellidos" => "Egocheaga"
            ]
            1 => array:2 [
              "nombre" => "Roberto"
              "apellidos" => "Alcázar"
            ]
            2 => array:2 [
              "nombre" => "José M."
              "apellidos" => "Lobos"
            ]
            3 => array:2 [
              "nombre" => "J. Luis"
              "apellidos" => "Górriz"
            ]
            4 => array:2 [
              "nombre" => "Alberto"
              "apellidos" => "Martínez-Castelao"
            ]
            5 => array:2 [
              "nombre" => "Ana"
              "apellidos" => "Pastor"
            ]
            6 => array:2 [
              "nombre" => "Isabel"
              "apellidos" => "Martínez"
            ]
            7 => array:2 [
              "nombre" => "Fernando"
              "apellidos" => "Caballero"
            ]
            8 => array:2 [
              "nombre" => "Marta"
              "apellidos" => "Sánchez-Celaya"
            ]
          ]
        ]
      ]
    ]
    "idiomaDefecto" => "es"
    "Traduccion" => array:1 [
      "en" => array:9 [
        "pii" => "X2013251412002256"
        "doi" => "10.3265/Nefrologia.pre2012.Sep.11367"
        "estado" => "S300"
        "subdocumento" => ""
        "abierto" => array:3 [
          "ES" => true
          "ES2" => true
          "LATM" => true
        ]
        "gratuito" => true
        "lecturas" => array:1 [
          "total" => 0
        ]
        "idiomaDefecto" => "en"
        "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X2013251412002256?idApp=UINPBA000064"
      ]
    ]
    "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X0211699512002259?idApp=UINPBA000064"
    "url" => "/02116995/0000003200000006/v0_201502091338/X0211699512002259/v0_201502091339/es/main.assets"
  ]
  "itemAnterior" => array:17 [
    "pii" => "X0211699512002275"
    "issn" => "02116995"
    "doi" => "10.3265/Nefrologia.pre2012.Jul.11465"
    "estado" => "S300"
    "fechaPublicacion" => "2012-11-01"
    "documento" => "article"
    "licencia" => "http://www.elsevier.com/open-access/userlicense/1.0/"
    "subdocumento" => "fla"
    "cita" => "Nefrologia. 2012;32:782-9"
    "abierto" => array:3 [
      "ES" => true
      "ES2" => true
      "LATM" => true
    ]
    "gratuito" => true
    "lecturas" => array:2 [
      "total" => 7718
      "formatos" => array:3 [
        "EPUB" => 318
        "HTML" => 6769
        "PDF" => 631
      ]
    ]
    "es" => array:12 [
      "idiomaDefecto" => true
      "titulo" => "Efecto de la modalidad de diálisis y otros factores de prescripción sobre las pérdidas proteicas peritoneales en diálisis peritoneal"
      "tienePdf" => "es"
      "tieneTextoCompleto" => "es"
      "tieneResumen" => array:2 [
        0 => "es"
        1 => "en"
      ]
      "paginas" => array:1 [
        0 => array:2 [
          "paginaInicial" => "782"
          "paginaFinal" => "789"
        ]
      ]
      "titulosAlternativos" => array:1 [
        "en" => array:1 [
          "titulo" => "Effect of dialysis modality and other prescription factors on peritoneal protein excretion in peritoneal dialysis"
        ]
      ]
      "contieneResumen" => array:2 [
        "es" => true
        "en" => true
      ]
      "contieneTextoCompleto" => array:1 [
        "es" => true
      ]
      "contienePdf" => array:1 [
        "es" => true
      ]
      "resumenGrafico" => array:2 [
        "original" => 0
        "multimedia" => array:8 [
          "identificador" => "fig1"
          "etiqueta" => "Tab.  1"
          "tipo" => "MULTIMEDIAFIGURA"
          "mostrarFloat" => true
          "mostrarDisplay" => false
          "copyright" => "Elsevier España"
          "figura" => array:1 [
            0 => array:4 [
              "imagen" => "11465_19759_29134_es_11465_t1.jpg"
              "Alto" => 350
              "Ancho" => 600
              "Tamanyo" => 188045
            ]
          ]
          "descripcion" => array:1 [
            "es" => "Características generales de los grupos de estudio al inicio de diálisis peritoneal"
          ]
        ]
      ]
      "autores" => array:1 [
        0 => array:2 [
          "autoresLista" => "Ana Rodríguez-Carmona, Miguel Pérez Fontán, Miguel Pérez-Fontán, Sonia Pértega Díaz, Sonia Pértega-Díaz, Beatriz López Calviño, Beatriz López-Calviño, Andrés López Muñiz, Andrés López-Muñiz, Teresa García Falcón, Teresa García-Falcón"
          "autores" => array:11 [
            0 => array:2 [
              "nombre" => "Ana"
              "apellidos" => "Rodríguez-Carmona"
            ]
            1 => array:2 [
              "nombre" => "Miguel"
              "apellidos" => "Pérez Fontán"
            ]
            2 => array:2 [
              "nombre" => "Miguel"
              "apellidos" => "Pérez-Fontán"
            ]
            3 => array:2 [
              "nombre" => "Sonia"
              "apellidos" => "Pértega Díaz"
            ]
            4 => array:2 [
              "nombre" => "Sonia"
              "apellidos" => "Pértega-Díaz"
            ]
            5 => array:2 [
              "nombre" => "Beatriz"
              "apellidos" => "López Calviño"
            ]
            6 => array:2 [
              "nombre" => "Beatriz"
              "apellidos" => "López-Calviño"
            ]
            7 => array:2 [
              "nombre" => "Andrés"
              "apellidos" => "López Muñiz"
            ]
            8 => array:2 [
              "nombre" => "Andrés"
              "apellidos" => "López-Muñiz"
            ]
            9 => array:2 [
              "nombre" => "Teresa"
              "apellidos" => "García Falcón"
            ]
            10 => array:2 [
              "nombre" => "Teresa"
              "apellidos" => "García-Falcón"
            ]
          ]
        ]
      ]
    ]
    "idiomaDefecto" => "es"
    "Traduccion" => array:1 [
      "en" => array:9 [
        "pii" => "X2013251412002272"
        "doi" => "10.3265/Nefrologia.pre2012.Jul.11465"
        "estado" => "S300"
        "subdocumento" => ""
        "abierto" => array:3 [
          "ES" => true
          "ES2" => true
          "LATM" => true
        ]
        "gratuito" => true
        "lecturas" => array:1 [
          "total" => 0
        ]
        "idiomaDefecto" => "en"
        "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X2013251412002272?idApp=UINPBA000064"
      ]
    ]
    "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X0211699512002275?idApp=UINPBA000064"
    "url" => "/02116995/0000003200000006/v0_201502091338/X0211699512002275/v0_201502091339/es/main.assets"
  ]
  "es" => array:12 [
    "idiomaDefecto" => true
    "titulo" => "El efecto de la pentoxifilina en la reducción de proteinuria en pacientes con diabetes tipo 2 con bloqueo del sistema de angiotensina: ensayo clínico doble ciego y aleatorizado"
    "tieneTextoCompleto" => 0
    "paginas" => array:1 [
      0 => array:2 [
        "paginaInicial" => "790"
        "paginaFinal" => "796"
      ]
    ]
    "autores" => array:1 [
      0 => array:3 [
        "autoresLista" => "Ali Ghorbani, Bita Omidvar, Seyed S. Beladi-Mousavi, Seyed Seifollah Beladi Mousavi, Elena Lak, Sima Vaziri"
        "autores" => array:10 [
          0 => array:3 [
            "nombre" => "Ali"
            "apellidos" => "Ghorbani"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">a</span>"
                "identificador" => "affa"
              ]
            ]
          ]
          1 => array:3 [
            "nombre" => "Ali"
            "apellidos" => "Ghorbani"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">b</span>"
                "identificador" => "affb"
              ]
            ]
          ]
          2 => array:3 [
            "nombre" => "Bita"
            "apellidos" => "Omidvar"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">c</span>"
                "identificador" => "affc"
              ]
            ]
          ]
          3 => array:3 [
            "nombre" => "Bita"
            "apellidos" => "Omidvar"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">d</span>"
                "identificador" => "affd"
              ]
            ]
          ]
          4 => array:4 [
            "nombre" => "Seyed S&#46;"
            "apellidos" => "Beladi-Mousavi"
            "email" => array:1 [
              0 => "dr&#46;beladimousavi&#64;ajums&#46;ac&#46;ir"
            ]
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">e</span>"
                "identificador" => "affe"
              ]
            ]
          ]
          5 => array:4 [
            "nombre" => "Seyed Seifollah"
            "apellidos" => "Beladi Mousavi"
            "email" => array:1 [
              0 => "dr&#46;beladimousavi&#64;ajums&#46;ac&#46;ir"
            ]
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">f</span>"
                "identificador" => "afff"
              ]
            ]
          ]
          6 => array:3 [
            "nombre" => "Elena"
            "apellidos" => "Lak"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">e</span>"
                "identificador" => "affe"
              ]
            ]
          ]
          7 => array:3 [
            "nombre" => "Elena"
            "apellidos" => "Lak"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">f</span>"
                "identificador" => "afff"
              ]
            ]
          ]
          8 => array:3 [
            "nombre" => "Sima"
            "apellidos" => "Vaziri"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">g</span>"
                "identificador" => "affg"
              ]
            ]
          ]
          9 => array:3 [
            "nombre" => "Sima"
            "apellidos" => "Vaziri"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">h</span>"
                "identificador" => "affh"
              ]
            ]
          ]
        ]
        "afiliaciones" => array:8 [
          0 => array:3 [
            "entidad" => "Department of Internal Medicine, Faculty of Medicine, Jundishapour University of Medical Sciences, Golestan Hospital, Ahvaz, Khuzestan, Iran, "
            "etiqueta" => "<span class="elsevierStyleSup">a</span>"
            "identificador" => "affa"
          ]
          1 => array:3 [
            "entidad" => "Department of Internal Medicine, Faculty of medicine, Jundishapour university of medical sciences, Ahvaz, Ira, Golestan Hospital, Ahvaz, Khuzestan, Irán, "
            "etiqueta" => "<span class="elsevierStyleSup">b</span>"
            "identificador" => "affb"
          ]
          2 => array:3 [
            "entidad" => "Department of Rheumatology, Faculty of Medicine, Jundishapur University of Medical Sciences, Golestan Hospital, Ahvaz, Khuzestan, Iran, "
            "etiqueta" => "<span class="elsevierStyleSup">c</span>"
            "identificador" => "affc"
          ]
          3 => array:3 [
            "entidad" => " Department of Rheumatology, Faculty of Medicine, Jundishapur University of Medical Sciences, Golestan Hospital, Ahvaz, Khuzestan, Irán, "
            "etiqueta" => "<span class="elsevierStyleSup">d</span>"
            "identificador" => "affd"
          ]
          4 => array:3 [
            "entidad" => "Department of Internal Medicine, Faculty of Medicine, Jundishapur University of Medical Sciences, Iman Hospital, Ahvaz, Khuzestan, Iran, "
            "etiqueta" => "<span class="elsevierStyleSup">e</span>"
            "identificador" => "affe"
          ]
          5 => array:3 [
            "entidad" => " Department of Internal Medicine, Faculty of Medicine, Jundishapur University of Medical Sciences, Iman Hospital, Ahvaz, Khuzestan, Irán, "
            "etiqueta" => "<span class="elsevierStyleSup">f</span>"
            "identificador" => "afff"
          ]
          6 => array:3 [
            "entidad" => "Department of Internal Medicine, Naft Hospital, Ahvaz, Khuzestan, Iran, "
            "etiqueta" => "<span class="elsevierStyleSup">g</span>"
            "identificador" => "affg"
          ]
          7 => array:3 [
            "entidad" => " Department of Internal Medicine, Naft Hospital, Ahvaz, Khuzestan, Irán, "
            "etiqueta" => "<span class="elsevierStyleSup">h</span>"
            "identificador" => "affh"
          ]
        ]
      ]
    ]
    "titulosAlternativos" => array:1 [
      "en" => array:1 [
        "titulo" => "The effect of pentoxifylline on reduction of proteinuria among patients with type 2 diabetes under blockade of angiotensin system&#58; a double blind and randomized clinical trial"
      ]
    ]
    "pdfFichero" => "P1-E544-S3760-A11242.pdf"
    "tienePdf" => true
    "PalabrasClave" => array:2 [
      "es" => array:3 [
        0 => array:4 [
          "clase" => "keyword"
          "titulo" => "Palabras clave"
          "identificador" => "xpalclavsec431759"
          "palabras" => array:1 [
            0 => "Pentoxifilina"
          ]
        ]
        1 => array:4 [
          "clase" => "keyword"
          "titulo" => "Palabras clave"
          "identificador" => "xpalclavsec431761"
          "palabras" => array:1 [
            0 => "Pentoxifilina"
          ]
        ]
        2 => array:4 [
          "clase" => "keyword"
          "titulo" => "Palabras clave"
          "identificador" => "xpalclavsec431763"
          "palabras" => array:1 [
            0 => "Nefropat&#237;a diab&#233;tica"
          ]
        ]
      ]
      "en" => array:3 [
        0 => array:4 [
          "clase" => "keyword"
          "titulo" => "Keywords"
          "identificador" => "xpalclavsec431760"
          "palabras" => array:1 [
            0 => "Proteinuria"
          ]
        ]
        1 => array:4 [
          "clase" => "keyword"
          "titulo" => "Keywords"
          "identificador" => "xpalclavsec431762"
          "palabras" => array:1 [
            0 => "Pentoxifylline"
          ]
        ]
        2 => array:4 [
          "clase" => "keyword"
          "titulo" => "Keywords"
          "identificador" => "xpalclavsec431764"
          "palabras" => array:1 [
            0 => "Diabetic Nephropathy"
          ]
        ]
      ]
    ]
    "tieneResumen" => true
    "resumen" => array:2 [
      "es" => array:1 [
        "resumen" => "<p class="elsevierStylePara">Aunque el bloqueo del sistema renina-angiotensina ha sido citado como el tratamiento inicial para la nefropat&#237;a diab&#233;tica &#40;ND&#41;&#44; en un n&#250;mero significativo de pacientes el avance de la enfermedad renal no se ve frenado en su totalidad por estos agentes&#46; Hemos realizado un ensayo cl&#237;nico doble ciego para valorar el efecto acumulativo de la pentoxifilina &#40;PTX&#41; en la reducci&#243;n de la proteinuria en pacientes con diabetes tipo 2 &#40;DM2&#41; con bloqueo del sistema de angiotensina&#46; La dosis de PTX utilizada en nuestro ensayo fue una cantidad baja de 400 mg diarios y&#44; en nuestra experiencia&#44; no logramos encontrar ning&#250;n art&#237;culo que evaluara el efecto antiprotein&#250;rico de la PTX con esta dosis&#46; De forma aleatoria&#44; se dividieron en dos grupos 100 pacientes con ND y proteinuria persistente a pesar del tratamiento con losart&#225;n y enalapril durante al menos tres meses antes de ser incluidos en el estudio&#46; El grupo de control &#40;n &#61; 50&#44; 26 hombres y 24 mujeres&#41; fueron tratados con losart&#225;n y enalapril&#44; mientras que el grupo de tratamiento &#40;grupo de PTX&#58; n &#61; 50&#44; 28 hombres y 22 mujeres&#41; recibieron losart&#225;n&#44; enalapril y 400 mg&#47;d&#237;a de pentoxifilina durante 6 meses&#46; Al comienzo del estudio no se encontraron diferencias significativas en las caracter&#237;sticas demogr&#225;ficas y cl&#237;nicas de los pacientes&#44; incluida la creatinina s&#233;rica&#44; HbA<span class="elsevierStyleInf">1c</span>&#44; presi&#243;n arterial y excreci&#243;n urinaria de prote&#237;nas entre los dos grupos &#40;p &#62; 0&#44;05&#41;&#46; En el grupo de PTX&#44; la tasa media de excreci&#243;n urinaria de prote&#237;na ha disminuido significativamente de 616&#44;66 a 378&#44;24 mg tras 3 meses &#40;p &#61; 0&#44;000&#41; y a 192&#44;05 mg tras 6 meses &#40;p &#61; 0&#44;000&#41;&#44; mientras que en el grupo de control no se han observado cambios significativos&#46; El beneficioso efecto antiprotein&#250;rico del PTX no estuvo asociado a la intensidad del cambio metab&#243;lico ni a la reducci&#243;n de la presi&#243;n arterial&#46; Adem&#225;s&#44; al final del estudio&#44; el aclaramiento medio de creatinina fue significativamente m&#225;s elevado en el grupo de PTX &#40;p &#61; 0&#44;04&#41;&#46; En conclusi&#243;n&#44; la PTX puede aportar en gran medida un efecto antiprotein&#250;rico acumulativo y ralentizar el grado de filtraci&#243;n glomerular en pacientes con DM2 con bloqueo del sistema de angiotensina&#46;</p>"
      ]
      "en" => array:1 [
        "resumen" => "<p class="elsevierStylePara">Although blockade of renin-angiotensin system have been cited as the first line of therapy for the management of diabetic nephropathy &#40;DN&#41;&#44; however in a substantial number of patients&#44; progression of renal disease are not completely halted by these agents&#46; We have conducted a double blinded clinical trial to assess the additive effect of pentoxifylline on reduction of proteinuria among patients with type 2 DM under blockade of angiotensin system&#46; The dosage of PTX used in our trial was at a low dosage of 400mg daily and to our knowledge&#44; we did not found article which evaluated the antiproteinuric effect of pentoxifylline in this dosage&#46; One hundred patients with DN and persistent proteinuria despite treatment with losartan and enalapril in at least 3 months before inclusion in the study were randomly assigned to two groups&#46; Control group &#40;n&#61;50&#44; 26 males and 24 females&#41; received losartan and enalapril&#44; while treatment group &#40;PTX Group&#41; &#40;n&#61;50&#44; 28 males and 22 females&#41; was given losartan&#44; enalapril and pentoxifylline 400mg&#47;day for 6 months&#46; At the beginning of the study there were no significant differences in demographic and clinical characteristics of patients including serum creatinine&#44; HbA1c&#44; blood pressure and urinary protein excretion between two groups &#40;P&#62;&#46;05&#41;&#46; In the PTX group&#44; the mean rate of urinary protein excretion have significantly decreased from 616&#46;66mg to 378&#46;24 after 3 months &#40;P&#61;&#46;000&#41; and to 192&#46;05mg after 6 months &#40;P&#61;&#46;000&#41; whereas no significant changes were observed in the control group&#46; The beneficial antiproteinuric effect of PTX was not associated to the degree of metabolic control and a reduction of blood pressure&#46; In addition&#44; at the end of study&#44; the mean clearance of creatinine was significantly higher in PTX group &#40;P&#61;&#46;04&#41;&#46; In conclusion&#44; PTX can significantly provide additive antiproteinuric effect and slow the decrease in GFR among patients with type 2 DM under blockade of angiotensin system&#46;</p>"
      ]
    ]
    "bibliografia" => array:2 [
      "titulo" => "Bibliograf&#237;a"
      "seccion" => array:1 [
        0 => array:1 [
          "bibliografiaReferencia" => array:43 [
            0 => array:3 [
              "identificador" => "bib1"
              "etiqueta" => "1"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "K/DOQI clinical practice guidelines and clinical practice recommendations for diabetes and chronic kidney disease. Am J Kidney Dis 2007;49(2 Suppl 2):S12. <a href="http://www.ncbi.nlm.nih.gov/pubmed/17276798" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            1 => array:3 [
              "identificador" => "bib2"
              "etiqueta" => "2"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "National Institutes of Health. Excerpts from United States Renal Data System 2000 Annual Data Report: atlas of end-stage renal disease in the United States: economic costs of ESRD. Am J Kidney Dis 2000;36:163-76."
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            2 => array:3 [
              "identificador" => "bib3"
              "etiqueta" => "3"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Gross JL, de Azevedo MJ, Silveiro SP, Canani LH,\u{A0}Caramori ML,\u{A0}Zelmanovitz T. Diabetic nephropathy: diagnosis, prevention, and treatment. Diabetes Care 2005;28:164-76. <a href="http://www.ncbi.nlm.nih.gov/pubmed/15616252" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            3 => array:3 [
              "identificador" => "bib4"
              "etiqueta" => "4"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Adler AI, Stevens RJ, Manley SE, Bilous RW,\u{A0}Cull CA,\u{A0}Holman RR;\u{A0}UKPDS GROUP. Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney Int 2003;63:225-32. <a href="http://www.ncbi.nlm.nih.gov/pubmed/12472787" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            4 => array:3 [
              "identificador" => "bib5"
              "etiqueta" => "5"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Estacio RO, Jeffers BW, Hiatf WR, Biggerstall SL, Gifford N, Schrier RW. The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non ¿ insulin ¿ dependent diabetes and hypertension. N Engl J Med 1998;338:645-52. <a href="http://www.ncbi.nlm.nih.gov/pubmed/9486993" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            5 => array:3 [
              "identificador" => "bib6"
              "etiqueta" => "6"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Hovind P, Rossing P, Tarnow L, Smidt UM, Parving HH. Progression of diabetic nephropathy. Kidney Int 2001;59:702-9. <a href="http://www.ncbi.nlm.nih.gov/pubmed/11168952" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            6 => array:3 [
              "identificador" => "bib7"
              "etiqueta" => "7"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Parving HH, Hommel E, Jensen BR, Hansen HP. Long-term beneficial effect of ACE inhibition on diabetic nephropathy in normotensive type 1 diabetic patients. Kidney Int 2001;60:228-34. <a href="http://www.ncbi.nlm.nih.gov/pubmed/11422755" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            7 => array:3 [
              "identificador" => "bib8"
              "etiqueta" => "8"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Lewis EJ, Hunsicker LG, Clarke WR, Berl T,\u{A0}Pohl MA,\u{A0}Lewis JB,\u{A0}et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001;345:851-60. <a href="http://www.ncbi.nlm.nih.gov/pubmed/11565517" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            8 => array:3 [
              "identificador" => "bib9"
              "etiqueta" => "9"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Brenner BM, Cooper ME, de Zeeuw D, Keane WF,\u{A0}Mitch WE,\u{A0}Parving HH,\u{A0}et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001;345:861-9. <a href="http://www.ncbi.nlm.nih.gov/pubmed/11565518" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            9 => array:3 [
              "identificador" => "bib10"
              "etiqueta" => "10"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Lewis E, Hunsicker L, Bain R, Rohde R. The\u{A0} effect\u{A0} of angiotensin converting enzyme inhibition on diabetic nephropathy. N Engl J Med 1993;329:1456-62. <a href="http://www.ncbi.nlm.nih.gov/pubmed/8413456" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            10 => array:3 [
              "identificador" => "bib11"
              "etiqueta" => "11"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "de Zeeuw D, Remuzzi G, Parving HH, Keane WF,\u{A0}Zhang Z,\u{A0}Shahinfar S,\u{A0}et al. Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL. Kidney Int 2004;65:2309-20. <a href="http://www.ncbi.nlm.nih.gov/pubmed/15149345" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            11 => array:3 [
              "identificador" => "bib12"
              "etiqueta" => "12"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Jafar TH, Stark PC, Schmid CH, Landa M,\u{A0}Maschio G,\u{A0}Marcantoni C, et al.;\u{A0}AIPRD Study Group. Angiotensin-Converting Enzymne Inhibition and Progression of Renal Diseaseet al. Proteinuria as a modifiable risk factor for the progression of non-diabetic renal disease. Kidney Int 2001;60:1131-40. <a href="http://www.ncbi.nlm.nih.gov/pubmed/11532109" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            12 => array:3 [
              "identificador" => "bib13"
              "etiqueta" => "13"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "ADVANCE Collaborative Group, Patel A, MacMahon S, Chalmers J,\u{A0}Neal B,\u{A0}Billot L,\u{A0}et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008;358:2560-72. <a href="http://www.ncbi.nlm.nih.gov/pubmed/18539916" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            13 => array:3 [
              "identificador" => "bib14"
              "etiqueta" => "14"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Basi S, Lewis JB. Microalbuminuria as a target to improve cardiovascular and renal outcomes. Am J Kidney Dis 2006;47:927-46. <a href="http://www.ncbi.nlm.nih.gov/pubmed/16731288" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:1 [
                        "itemHostRev" => array:3 [
                          "pii" => "S0140673606692519"
                          "estado" => "S300"
                          "issn" => "01406736"
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            14 => array:3 [
              "identificador" => "bib15"
              "etiqueta" => "15"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Fliser D, Wagner KK, Loos A, Tsikas D,\u{A0}Haller H.\u{A0}Chronic angiotensin II receptor blockade reduces (intra)renal vascular resistance in patients with type 2 diabetes. J Am Soc Nephrol 2005;16:1135-40. <a href="http://www.ncbi.nlm.nih.gov/pubmed/15716329" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            15 => array:3 [
              "identificador" => "bib16"
              "etiqueta" => "16"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Hilgers KF, Veelken R. Type 2 diabetic nephropathy: never too early to treat? J Am Soc Nephrol 2005;16:574-5. <a href="http://www.ncbi.nlm.nih.gov/pubmed/15703269" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            16 => array:3 [
              "identificador" => "bib17"
              "etiqueta" => "17"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Nagai Y, Yao L, Kobori H, Miyata K,\u{A0}Ozawa Y,\u{A0}Miyatake A,\u{A0}et al. Temporary angiotensin II blockade at the prediabetic stage attenuates the development of renal injury in type 2 diabetic rats. J Am Soc Nephrol 2005;16:703-11. <a href="http://www.ncbi.nlm.nih.gov/pubmed/15647337" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            17 => array:3 [
              "identificador" => "bib18"
              "etiqueta" => "18"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Vasylyeva TL, Chen X, Ferry RJ Jr. Insulin-like growth factor binding protein-3 mediates cytokine-induced mesangial cell apoptosis. Growth Horm IGF Res 2005;15:207-14. <a href="http://www.ncbi.nlm.nih.gov/pubmed/15935983" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            18 => array:3 [
              "identificador" => "bib19"
              "etiqueta" => "19"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Lin CL, Wang JY, Huang YT, Kuo YH,\u{A0}Surendran K,\u{A0}Wang FS. Wnt/beta-catenin signaling modulates survival of high glucose-stressed mesangial cells. J Am Soc Nephrol 2006;17:2812-20. <a href="http://www.ncbi.nlm.nih.gov/pubmed/16943306" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            19 => array:3 [
              "identificador" => "bib20"
              "etiqueta" => "20"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Maxhimer JB, Somenek M, Rao G, Pesce CE,\u{A0}Baldwin D Jr,\u{A0}Gattuso P,\u{A0}et al. Heparanase-1 gene expression and regulation by high glucose in renal epithelial cells: a potential role in the pathogenesis of proteinuria in diabetic patients. Diabetes 2005;54:2172-8. <a href="http://www.ncbi.nlm.nih.gov/pubmed/15983219" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            20 => array:3 [
              "identificador" => "bib21"
              "etiqueta" => "21"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "van den Hoven MJ, Rops AL, Bakker MA, Aten J,\u{A0}Rutjes N,\u{A0}Roestenberg P,\u{A0}et al. Increased expression of heparanase in overt diabetic nephropathy. Kidney Int 2006;70:2100-8. <a href="http://www.ncbi.nlm.nih.gov/pubmed/17051139" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            21 => array:3 [
              "identificador" => "bib22"
              "etiqueta" => "22"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Nguyen G. Renin/prorenin receptors. Kidney Int 2006;69:1503-9."
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            22 => array:3 [
              "identificador" => "bib23"
              "etiqueta" => "23"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Ichihara A, Suzuki F, Nakagawa T, Kaneshiro Y,\u{A0}Takemitsu T,\u{A0}Sakoda M,\u{A0}et al. Prorenin receptor blockade inhibits development of glomerulosclerosis in diabetic angiotensin II type 1a receptor-deficient mice. J Am Soc Nephrol 2006;17:1950-61. <a href="http://www.ncbi.nlm.nih.gov/pubmed/16738017" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            23 => array:3 [
              "identificador" => "bib24"
              "etiqueta" => "24"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Hohenstein B, Hausknecht B, Boehmer K, Riess R,\u{A0}Brekken RA,\u{A0}Hugo CP. Local VEGF activity but not VEGF expression is tightly regulated during diabetic nephropathy in man. Kidney Int 2006;69:1654-61. <a href="http://www.ncbi.nlm.nih.gov/pubmed/16541023" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            24 => array:3 [
              "identificador" => "bib25"
              "etiqueta" => "25"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "de Vriese AS, Tilton RG, Elger M, \u{A0}Stephan CC,\u{A0}Kriz W,\u{A0}Lameire NH. Antibodies against vascular endothelial growth factor improve early renal dysfunction in experimental diabetes. J Am Soc Nephrol 2001;12:993-1000. <a href="http://www.ncbi.nlm.nih.gov/pubmed/11316858" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            25 => array:3 [
              "identificador" => "bib26"
              "etiqueta" => "26"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Hayashida T, Schnaper HW. High ambient glucose enhances sensitivity to TGF-beta1 via extracellular signal--regulated kinase and protein kinase Cdelta activities in human mesangial cells. J Am Soc Nephrol 2004;15:2032-41. <a href="http://www.ncbi.nlm.nih.gov/pubmed/15284289" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            26 => array:3 [
              "identificador" => "bib27"
              "etiqueta" => "27"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Festa A, D¿Agostino R Jr, Howard G, Mykkanen L, Tracy R, Haffner S. Inflammation and microalbuminuria in nondiabetic and type 2 diabetic subjects: The Insulin Resistance Atherosclerosis Study. Kidney Int 2000;58:1703-10. <a href="http://www.ncbi.nlm.nih.gov/pubmed/11012904" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            27 => array:3 [
              "identificador" => "bib28"
              "etiqueta" => "28"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Navarro JF, Mora C, Macía M, García J. Inflammatory parameters are independently associated with urinary albumin excretion in type 2 diabetes mellitus. Am J Kidney Dis 2003;42:53-61. <a href="http://www.ncbi.nlm.nih.gov/pubmed/12830456" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            28 => array:3 [
              "identificador" => "bib29"
              "etiqueta" => "29"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Navarro J. Diabetic nephropathy: A matter of inflammation? Nefrologia 2003;23:381-9. <a href="http://www.ncbi.nlm.nih.gov/pubmed/14658163" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            29 => array:3 [
              "identificador" => "bib30"
              "etiqueta" => "30"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "30.Gruden G, Setti G, Hayward A, Sugden D,\u{A0}Duggan S,\u{A0}Burt D,\u{A0}et al. Mechanical stretch induces monocyte chemoattractant activity via an NF-kappaB-dependent monocyte chemoattractant protein-1-mediated pathway in human mesangial cells: inhibition by rosiglitazone. J Am Soc Nephrol 2005;16:688-96. <a href="http://www.ncbi.nlm.nih.gov/pubmed/15677312" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            30 => array:3 [
              "identificador" => "bib31"
              "etiqueta" => "31"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Akahori H, Ota T, Torita M, Ando H,\u{A0}Kaneko S,\u{A0}Takamura T. Tranilast prevents the progression of experimental diabetic nephropathy through suppression of enhanced extracellular matrix gene expression. J Pharmacol Exp Ther 2005;314:514-21. <a href="http://www.ncbi.nlm.nih.gov/pubmed/15857946" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            31 => array:3 [
              "identificador" => "bib32"
              "etiqueta" => "32"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Soma J, Sato K, Saito H, Tsuchiya Y. Effect of tranilast in early-stage diabetic nephropathy. Nephrol Dial Transplant 2006;21:2795-9. <a href="http://www.ncbi.nlm.nih.gov/pubmed/16820373" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            32 => array:3 [
              "identificador" => "bib33"
              "etiqueta" => "33"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Soma J, Sugawara T, Huang YD,\u{A0}Nakajima J, Kawamura M. Tranilast slows the progression of advanced diabetic nephropathy. Nephron 2002;92:693-8. <a href="http://www.ncbi.nlm.nih.gov/pubmed/12372957" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            33 => array:3 [
              "identificador" => "bib34"
              "etiqueta" => "34"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "34.\u{A0}Abdollahi M,\u{A0}Chan TS,\u{A0}Subrahmanyam V,\u{A0}O'Brien PJ. Effects of phosphodiesterase 3, 4, 5 inhibitors on hepatocyte cAMP levels, glycogenolysis, gluconeogenesis and susceptibility to a mitochondrial toxin. Mol Cell Biochem 2003;252:205-11. <a href="http://www.ncbi.nlm.nih.gov/pubmed/14577594" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            34 => array:3 [
              "identificador" => "bib35"
              "etiqueta" => "35"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "35.\u{A0}Noyan T,\u{A0}Onem O,\u{A0}Ramazan Sekeroglu M,\u{A0}Koseoglu B,\u{A0}Dulger H,\u{A0}Bayram I, et al. Effects of erythropoietin and pentoxifylline on the oxidant and antioxidant systems in the experimental short bowel syndrome. Cell Biochem Funct 2003;21:49-54. <a href="http://www.ncbi.nlm.nih.gov/pubmed/12579521" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            35 => array:3 [
              "identificador" => "bib36"
              "etiqueta" => "36"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Navarro J, Mora C, Muros M, Macía M, García J. Effects of pentoxifylline administration on urinary N-acetyl-beta-glucosaminidase excretion in type 2 diabetic patients: A short-term, prospective, randomised study. Am J Kidney Dis 2003;42:264-70. <a href="http://www.ncbi.nlm.nih.gov/pubmed/12900807" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            36 => array:3 [
              "identificador" => "bib37"
              "etiqueta" => "37"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "37.\u{A0}Navarro JF, Mora-Fernández C. The role of TNF-alpha in diabetic nephropathy: Pathogenic and therapeutic implications. Cytokine Growth Factor Rev 2006;17:441-50. <a href="http://www.ncbi.nlm.nih.gov/pubmed/17113815" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            37 => array:3 [
              "identificador" => "bib38"
              "etiqueta" => "38"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Navarro J, Mora C, Muros M, Macía M, García J. Additive antiproteinuric effect of pentoxifylline in patients with type 2 diabetes under angiotensin II receptor blockade: A short-term, randomized, controlled trial. J Am Soc Nephrol 2005;16:2119-26. <a href="http://www.ncbi.nlm.nih.gov/pubmed/15917336" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            38 => array:3 [
              "identificador" => "bib39"
              "etiqueta" => "39"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Harmankaya O, Seber S, Yilmaz M. Combination of pentoxifylline with angiotensin converting enzyme inhibitors produces an additional reduction in microalbuminuria in hypertensive type 2 diabetic patients. Ren Fail 2003;25:465-70. <a href="http://www.ncbi.nlm.nih.gov/pubmed/12803510" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            39 => array:3 [
              "identificador" => "bib40"
              "etiqueta" => "40"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Diskin CJ, Stokes TJ, Dansby LM, Radcliff L, Carter TB. Will the addition of pentoxifylline reduce proteinuria in patients with diabetic glomerulosclerosis refractory to maximal doses of both an angiotensin-converting enzyme inhibitor and an angiotensin receptor blocker? J Nephrol 2007;20:410-6. <a href="http://www.ncbi.nlm.nih.gov/pubmed/17879206" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            40 => array:3 [
              "identificador" => "bib41"
              "etiqueta" => "41"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Aminorroaya A, Janghorbani M, Rezvanian H, Aminian T, Gharavi M, Amini M. Comparison of the effect of pentoxifylline and captopril on proteinuria in patients with type 2 diabetes mellitus. Nephron Clin Pract 2005;99:c73-7. <a href="http://www.ncbi.nlm.nih.gov/pubmed/15665549" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            41 => array:3 [
              "identificador" => "bib42"
              "etiqueta" => "42"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Rodríguez-Morán M, Guerrero-Romero F. Pentoxifylline is as effective as captopril in the reduction of microalbuminuria in non-hypertensive type 2 diabetic patients--a randomized, equivalent trial. Clin Nephrol 2005;64:91-7. <a href="http://www.ncbi.nlm.nih.gov/pubmed/16114784" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            42 => array:3 [
              "identificador" => "bib43"
              "etiqueta" => "43"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "43.\u{A0}Perkins RM, Aboudara MC, Uy AL, Olson SW, Cushner HM, Yuan CM. Effect of pentoxifylline on GFR decline in CKD: a pilot, double-blind, randomized, placebo-controlled trial. Am J Kidney Dis 2009;53:606-16. <a href="http://www.ncbi.nlm.nih.gov/pubmed/19216016" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
          ]
        ]
      ]
    ]
  ]
  "idiomaDefecto" => "es"
  "url" => "/02116995/0000003200000006/v0_201502091338/X0211699512002267/v0_201502091339/es/main.assets"
  "Apartado" => array:4 [
    "identificador" => "35393"
    "tipo" => "SECCION"
    "es" => array:2 [
      "titulo" => "Artículos Originales"
      "idiomaDefecto" => true
    ]
    "idiomaDefecto" => "es"
  ]
  "PDF" => "https://static.elsevier.es/multimedia/02116995/0000003200000006/v0_201502091338/X0211699512002267/v0_201502091339/es/P1-E544-S3760-A11242.pdf?idApp=UINPBA000064&text.app=https://revistanefrologia.com/"
  "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X0211699512002267?idApp=UINPBA000064"
]
Compartir
Información de la revista

Estadísticas

Siga este enlace para acceder al texto completo del artículo

El efecto de la pentoxifilina en la reducción de proteinuria en pacientes con diabetes tipo 2 con bloqueo del sistema de angiotensina: ensayo clínico doble ciego y aleatorizado
The effect of pentoxifylline on reduction of proteinuria among patients with type 2 diabetes under blockade of angiotensin system: a double blind and randomized clinical trial
Ali Ghorbania, Ali Ghorbanib, Bita Omidvarc, Bita Omidvard, Seyed S. Beladi-Mousavie, Seyed Seifollah Beladi Mousavif, Elena Lake, Elena Lakf, Sima Vazirig, Sima Vazirih
a Department of Internal Medicine, Faculty of Medicine, Jundishapour University of Medical Sciences, Golestan Hospital, Ahvaz, Khuzestan, Iran,
b Department of Internal Medicine, Faculty of medicine, Jundishapour university of medical sciences, Ahvaz, Ira, Golestan Hospital, Ahvaz, Khuzestan, Irán,
c Department of Rheumatology, Faculty of Medicine, Jundishapur University of Medical Sciences, Golestan Hospital, Ahvaz, Khuzestan, Iran,
d Department of Rheumatology, Faculty of Medicine, Jundishapur University of Medical Sciences, Golestan Hospital, Ahvaz, Khuzestan, Irán,
e Department of Internal Medicine, Faculty of Medicine, Jundishapur University of Medical Sciences, Iman Hospital, Ahvaz, Khuzestan, Iran,
f Department of Internal Medicine, Faculty of Medicine, Jundishapur University of Medical Sciences, Iman Hospital, Ahvaz, Khuzestan, Irán,
g Department of Internal Medicine, Naft Hospital, Ahvaz, Khuzestan, Iran,
h Department of Internal Medicine, Naft Hospital, Ahvaz, Khuzestan, Irán,
Leído
20666
Veces
se ha leído el artículo
4418
Total PDF
16248
Total HTML
Compartir estadísticas
 array:21 [
  "pii" => "X0211699512002267"
  "issn" => "02116995"
  "doi" => "10.3265/Nefrologia.pre2012.Jun.11242"
  "estado" => "S300"
  "fechaPublicacion" => "2012-11-01"
  "documento" => "article"
  "licencia" => "http://www.elsevier.com/open-access/userlicense/1.0/"
  "subdocumento" => "fla"
  "cita" => "Nefrologia. 2012;32:790-6"
  "abierto" => array:3 [
    "ES" => true
    "ES2" => true
    "LATM" => true
  ]
  "gratuito" => true
  "lecturas" => array:2 [
    "total" => 12406
    "formatos" => array:3 [
      "EPUB" => 346
      "HTML" => 10789
      "PDF" => 1271
    ]
  ]
  "Traduccion" => array:1 [
    "en" => array:17 [
      "pii" => "X2013251412002264"
      "issn" => "20132514"
      "doi" => "10.3265/Nefrologia.pre2012.Jun.11242"
      "estado" => "S300"
      "fechaPublicacion" => "2012-11-01"
      "documento" => "article"
      "licencia" => "http://www.elsevier.com/open-access/userlicense/1.0/"
      "subdocumento" => "fla"
      "cita" => "Nefrologia &#40;English Version&#41;. 2012;32:790-6"
      "abierto" => array:3 [
        "ES" => true
        "ES2" => true
        "LATM" => true
      ]
      "gratuito" => true
      "lecturas" => array:2 [
        "total" => 6654
        "formatos" => array:3 [
          "EPUB" => 295
          "HTML" => 5475
          "PDF" => 884
        ]
      ]
      "en" => array:12 [
        "idiomaDefecto" => true
        "titulo" => "The effect of pentoxifylline on reduction of proteinuria among patients with type 2 diabetes under blockade of angiotensin system&#58; a double blind and randomized clinical trial"
        "tienePdf" => "en"
        "tieneTextoCompleto" => "en"
        "tieneResumen" => array:2 [
          0 => "es"
          1 => "en"
        ]
        "paginas" => array:1 [
          0 => array:2 [
            "paginaInicial" => "790"
            "paginaFinal" => "796"
          ]
        ]
        "titulosAlternativos" => array:1 [
          "es" => array:1 [
            "titulo" => "El efecto de la pentoxifilina en la reducci&#243;n de proteinuria en pacientes con diabetes tipo 2 con bloqueo del sistema de angiotensina&#58; ensayo cl&#237;nico doble ciego y aleatorizado"
          ]
        ]
        "contieneResumen" => array:2 [
          "es" => true
          "en" => true
        ]
        "contieneTextoCompleto" => array:1 [
          "en" => true
        ]
        "contienePdf" => array:1 [
          "en" => true
        ]
        "resumenGrafico" => array:2 [
          "original" => 0
          "multimedia" => array:8 [
            "identificador" => "fig1"
            "etiqueta" => "Tab.  1"
            "tipo" => "MULTIMEDIAFIGURA"
            "mostrarFloat" => true
            "mostrarDisplay" => false
            "copyright" => "Elsevier Espa&#241;a"
            "figura" => array:1 [
              0 => array:4 [
                "imagen" => "11242_16025_23451_en_t111242.jpg"
                "Alto" => 639
                "Ancho" => 2180
                "Tamanyo" => 413272
              ]
            ]
            "descripcion" => array:1 [
              "en" => "Baseline demographic and clinical characteristics of patients"
            ]
          ]
        ]
        "autores" => array:1 [
          0 => array:2 [
            "autoresLista" => "Ali Ghorbani, Bita Omidvar, Seyed S&#46; Beladi-Mousavi, Seyed Seifollah Beladi Mousavi, Elena Lak, Sima Vaziri"
            "autores" => array:10 [
              0 => array:2 [
                "nombre" => "Ali"
                "apellidos" => "Ghorbani"
              ]
              1 => array:2 [
                "nombre" => "Ali"
                "apellidos" => "Ghorbani"
              ]
              2 => array:2 [
                "nombre" => "Bita"
                "apellidos" => "Omidvar"
              ]
              3 => array:2 [
                "nombre" => "Bita"
                "apellidos" => "Omidvar"
              ]
              4 => array:2 [
                "nombre" => "Seyed S&#46;"
                "apellidos" => "Beladi-Mousavi"
              ]
              5 => array:2 [
                "nombre" => "Seyed Seifollah"
                "apellidos" => "Beladi Mousavi"
              ]
              6 => array:2 [
                "nombre" => "Elena"
                "apellidos" => "Lak"
              ]
              7 => array:2 [
                "nombre" => "Elena"
                "apellidos" => "Lak"
              ]
              8 => array:2 [
                "nombre" => "Sima"
                "apellidos" => "Vaziri"
              ]
              9 => array:2 [
                "nombre" => "Sima"
                "apellidos" => "Vaziri"
              ]
            ]
          ]
        ]
      ]
      "idiomaDefecto" => "en"
      "Traduccion" => array:1 [
        "es" => array:9 [
          "pii" => "X0211699512002267"
          "doi" => "10.3265/Nefrologia.pre2012.Jun.11242"
          "estado" => "S300"
          "subdocumento" => ""
          "abierto" => array:3 [
            "ES" => true
            "ES2" => true
            "LATM" => true
          ]
          "gratuito" => true
          "lecturas" => array:1 [
            "total" => 0
          ]
          "idiomaDefecto" => "es"
          "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X0211699512002267?idApp=UINPBA000064"
        ]
      ]
      "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X2013251412002264?idApp=UINPBA000064"
      "url" => "/20132514/0000003200000006/v0_201502091602/X2013251412002264/v0_201502091603/en/main.assets"
    ]
  ]
  "itemSiguiente" => array:17 [
    "pii" => "X0211699512002259"
    "issn" => "02116995"
    "doi" => "10.3265/Nefrologia.pre2012.Sep.11367"
    "estado" => "S300"
    "fechaPublicacion" => "2012-11-01"
    "documento" => "article"
    "licencia" => "http://www.elsevier.com/open-access/userlicense/1.0/"
    "subdocumento" => "fla"
    "cita" => "Nefrologia. 2012;32:797-808"
    "abierto" => array:3 [
      "ES" => true
      "ES2" => true
      "LATM" => true
    ]
    "gratuito" => true
    "lecturas" => array:2 [
      "total" => 8733
      "formatos" => array:3 [
        "EPUB" => 313
        "HTML" => 7759
        "PDF" => 661
      ]
    ]
    "es" => array:12 [
      "idiomaDefecto" => true
      "titulo" => "Conocimiento y aplicaci&#243;n en la pr&#225;ctica real del Documento de consenso S&#46;E&#46;N&#46;-semFYC sobre la enfermedad renal cr&#243;nica"
      "tienePdf" => "es"
      "tieneTextoCompleto" => "es"
      "tieneResumen" => array:2 [
        0 => "es"
        1 => "en"
      ]
      "paginas" => array:1 [
        0 => array:2 [
          "paginaInicial" => "797"
          "paginaFinal" => "808"
        ]
      ]
      "titulosAlternativos" => array:1 [
        "en" => array:1 [
          "titulo" => "Awareness and implementation in daily practice of the S&#46;E&#46;N&#46;-semFYC consensus document on chronic kidney disease"
        ]
      ]
      "contieneResumen" => array:2 [
        "es" => true
        "en" => true
      ]
      "contieneTextoCompleto" => array:1 [
        "es" => true
      ]
      "contienePdf" => array:1 [
        "es" => true
      ]
      "resumenGrafico" => array:2 [
        "original" => 0
        "multimedia" => array:8 [
          "identificador" => "fig1"
          "etiqueta" => "Tab.  1"
          "tipo" => "MULTIMEDIAFIGURA"
          "mostrarFloat" => true
          "mostrarDisplay" => false
          "copyright" => "Elsevier Espa&#241;a"
          "figura" => array:1 [
            0 => array:4 [
              "imagen" => "11367_19759_26453_es_11367_t1.jpg"
              "Alto" => 738
              "Ancho" => 600
              "Tamanyo" => 570988
            ]
          ]
          "descripcion" => array:1 [
            "es" => "Texto de las recomendaciones de contexto evaluadas en el estudio"
          ]
        ]
      ]
      "autores" => array:1 [
        0 => array:2 [
          "autoresLista" => "M&#46; Isabel Egocheaga, Roberto Alc&#225;zar, Jos&#233; M&#46; Lobos, J&#46; Luis G&#243;rriz, Alberto Mart&#237;nez-Castelao, Ana Pastor, Isabel Mart&#237;nez, Fernando Caballero, Marta S&#225;nchez-Celaya"
          "autores" => array:9 [
            0 => array:2 [
              "nombre" => "M&#46; Isabel"
              "apellidos" => "Egocheaga"
            ]
            1 => array:2 [
              "nombre" => "Roberto"
              "apellidos" => "Alc&#225;zar"
            ]
            2 => array:2 [
              "nombre" => "Jos&#233; M&#46;"
              "apellidos" => "Lobos"
            ]
            3 => array:2 [
              "nombre" => "J&#46; Luis"
              "apellidos" => "G&#243;rriz"
            ]
            4 => array:2 [
              "nombre" => "Alberto"
              "apellidos" => "Mart&#237;nez-Castelao"
            ]
            5 => array:2 [
              "nombre" => "Ana"
              "apellidos" => "Pastor"
            ]
            6 => array:2 [
              "nombre" => "Isabel"
              "apellidos" => "Mart&#237;nez"
            ]
            7 => array:2 [
              "nombre" => "Fernando"
              "apellidos" => "Caballero"
            ]
            8 => array:2 [
              "nombre" => "Marta"
              "apellidos" => "S&#225;nchez-Celaya"
            ]
          ]
        ]
      ]
    ]
    "idiomaDefecto" => "es"
    "Traduccion" => array:1 [
      "en" => array:9 [
        "pii" => "X2013251412002256"
        "doi" => "10.3265/Nefrologia.pre2012.Sep.11367"
        "estado" => "S300"
        "subdocumento" => ""
        "abierto" => array:3 [
          "ES" => true
          "ES2" => true
          "LATM" => true
        ]
        "gratuito" => true
        "lecturas" => array:1 [
          "total" => 0
        ]
        "idiomaDefecto" => "en"
        "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X2013251412002256?idApp=UINPBA000064"
      ]
    ]
    "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X0211699512002259?idApp=UINPBA000064"
    "url" => "/02116995/0000003200000006/v0_201502091338/X0211699512002259/v0_201502091339/es/main.assets"
  ]
  "itemAnterior" => array:17 [
    "pii" => "X0211699512002275"
    "issn" => "02116995"
    "doi" => "10.3265/Nefrologia.pre2012.Jul.11465"
    "estado" => "S300"
    "fechaPublicacion" => "2012-11-01"
    "documento" => "article"
    "licencia" => "http://www.elsevier.com/open-access/userlicense/1.0/"
    "subdocumento" => "fla"
    "cita" => "Nefrologia. 2012;32:782-9"
    "abierto" => array:3 [
      "ES" => true
      "ES2" => true
      "LATM" => true
    ]
    "gratuito" => true
    "lecturas" => array:2 [
      "total" => 7718
      "formatos" => array:3 [
        "EPUB" => 318
        "HTML" => 6769
        "PDF" => 631
      ]
    ]
    "es" => array:12 [
      "idiomaDefecto" => true
      "titulo" => "Efecto de la modalidad de di&#225;lisis y otros factores de prescripci&#243;n sobre las p&#233;rdidas proteicas peritoneales en di&#225;lisis peritoneal"
      "tienePdf" => "es"
      "tieneTextoCompleto" => "es"
      "tieneResumen" => array:2 [
        0 => "es"
        1 => "en"
      ]
      "paginas" => array:1 [
        0 => array:2 [
          "paginaInicial" => "782"
          "paginaFinal" => "789"
        ]
      ]
      "titulosAlternativos" => array:1 [
        "en" => array:1 [
          "titulo" => "Effect of dialysis modality and other prescription factors on peritoneal protein excretion in peritoneal dialysis"
        ]
      ]
      "contieneResumen" => array:2 [
        "es" => true
        "en" => true
      ]
      "contieneTextoCompleto" => array:1 [
        "es" => true
      ]
      "contienePdf" => array:1 [
        "es" => true
      ]
      "resumenGrafico" => array:2 [
        "original" => 0
        "multimedia" => array:8 [
          "identificador" => "fig1"
          "etiqueta" => "Tab.  1"
          "tipo" => "MULTIMEDIAFIGURA"
          "mostrarFloat" => true
          "mostrarDisplay" => false
          "copyright" => "Elsevier Espa&#241;a"
          "figura" => array:1 [
            0 => array:4 [
              "imagen" => "11465_19759_29134_es_11465_t1.jpg"
              "Alto" => 350
              "Ancho" => 600
              "Tamanyo" => 188045
            ]
          ]
          "descripcion" => array:1 [
            "es" => "Caracter&#237;sticas generales de los grupos de estudio al inicio de di&#225;lisis peritoneal"
          ]
        ]
      ]
      "autores" => array:1 [
        0 => array:2 [
          "autoresLista" => "Ana Rodr&#237;guez-Carmona, Miguel P&#233;rez Font&#225;n, Miguel P&#233;rez-Font&#225;n, Sonia P&#233;rtega D&#237;az, Sonia P&#233;rtega-D&#237;az, Beatriz L&#243;pez Calvi&#241;o, Beatriz L&#243;pez-Calvi&#241;o, Andr&#233;s L&#243;pez Mu&#241;iz, Andr&#233;s L&#243;pez-Mu&#241;iz, Teresa Garc&#237;a Falc&#243;n, Teresa Garc&#237;a-Falc&#243;n"
          "autores" => array:11 [
            0 => array:2 [
              "nombre" => "Ana"
              "apellidos" => "Rodr&#237;guez-Carmona"
            ]
            1 => array:2 [
              "nombre" => "Miguel"
              "apellidos" => "P&#233;rez Font&#225;n"
            ]
            2 => array:2 [
              "nombre" => "Miguel"
              "apellidos" => "P&#233;rez-Font&#225;n"
            ]
            3 => array:2 [
              "nombre" => "Sonia"
              "apellidos" => "P&#233;rtega D&#237;az"
            ]
            4 => array:2 [
              "nombre" => "Sonia"
              "apellidos" => "P&#233;rtega-D&#237;az"
            ]
            5 => array:2 [
              "nombre" => "Beatriz"
              "apellidos" => "L&#243;pez Calvi&#241;o"
            ]
            6 => array:2 [
              "nombre" => "Beatriz"
              "apellidos" => "L&#243;pez-Calvi&#241;o"
            ]
            7 => array:2 [
              "nombre" => "Andr&#233;s"
              "apellidos" => "L&#243;pez Mu&#241;iz"
            ]
            8 => array:2 [
              "nombre" => "Andr&#233;s"
              "apellidos" => "L&#243;pez-Mu&#241;iz"
            ]
            9 => array:2 [
              "nombre" => "Teresa"
              "apellidos" => "Garc&#237;a Falc&#243;n"
            ]
            10 => array:2 [
              "nombre" => "Teresa"
              "apellidos" => "Garc&#237;a-Falc&#243;n"
            ]
          ]
        ]
      ]
    ]
    "idiomaDefecto" => "es"
    "Traduccion" => array:1 [
      "en" => array:9 [
        "pii" => "X2013251412002272"
        "doi" => "10.3265/Nefrologia.pre2012.Jul.11465"
        "estado" => "S300"
        "subdocumento" => ""
        "abierto" => array:3 [
          "ES" => true
          "ES2" => true
          "LATM" => true
        ]
        "gratuito" => true
        "lecturas" => array:1 [
          "total" => 0
        ]
        "idiomaDefecto" => "en"
        "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X2013251412002272?idApp=UINPBA000064"
      ]
    ]
    "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X0211699512002275?idApp=UINPBA000064"
    "url" => "/02116995/0000003200000006/v0_201502091338/X0211699512002275/v0_201502091339/es/main.assets"
  ]
  "es" => array:12 [
    "idiomaDefecto" => true
    "titulo" => "El efecto de la pentoxifilina en la reducci&#243;n de proteinuria en pacientes con diabetes tipo 2 con bloqueo del sistema de angiotensina&#58; ensayo cl&#237;nico doble ciego y aleatorizado"
    "tieneTextoCompleto" => 0
    "paginas" => array:1 [
      0 => array:2 [
        "paginaInicial" => "790"
        "paginaFinal" => "796"
      ]
    ]
    "autores" => array:1 [
      0 => array:3 [
        "autoresLista" => "Ali Ghorbani, Bita Omidvar, Seyed S&#46; Beladi-Mousavi, Seyed Seifollah Beladi Mousavi, Elena Lak, Sima Vaziri"
        "autores" => array:10 [
          0 => array:3 [
            "nombre" => "Ali"
            "apellidos" => "Ghorbani"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">a</span>"
                "identificador" => "affa"
              ]
            ]
          ]
          1 => array:3 [
            "nombre" => "Ali"
            "apellidos" => "Ghorbani"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">b</span>"
                "identificador" => "affb"
              ]
            ]
          ]
          2 => array:3 [
            "nombre" => "Bita"
            "apellidos" => "Omidvar"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">c</span>"
                "identificador" => "affc"
              ]
            ]
          ]
          3 => array:3 [
            "nombre" => "Bita"
            "apellidos" => "Omidvar"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">d</span>"
                "identificador" => "affd"
              ]
            ]
          ]
          4 => array:4 [
            "nombre" => "Seyed S&#46;"
            "apellidos" => "Beladi-Mousavi"
            "email" => array:1 [
              0 => "dr&#46;beladimousavi&#64;ajums&#46;ac&#46;ir"
            ]
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">e</span>"
                "identificador" => "affe"
              ]
            ]
          ]
          5 => array:4 [
            "nombre" => "Seyed Seifollah"
            "apellidos" => "Beladi Mousavi"
            "email" => array:1 [
              0 => "dr&#46;beladimousavi&#64;ajums&#46;ac&#46;ir"
            ]
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">f</span>"
                "identificador" => "afff"
              ]
            ]
          ]
          6 => array:3 [
            "nombre" => "Elena"
            "apellidos" => "Lak"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">e</span>"
                "identificador" => "affe"
              ]
            ]
          ]
          7 => array:3 [
            "nombre" => "Elena"
            "apellidos" => "Lak"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">f</span>"
                "identificador" => "afff"
              ]
            ]
          ]
          8 => array:3 [
            "nombre" => "Sima"
            "apellidos" => "Vaziri"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">g</span>"
                "identificador" => "affg"
              ]
            ]
          ]
          9 => array:3 [
            "nombre" => "Sima"
            "apellidos" => "Vaziri"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">h</span>"
                "identificador" => "affh"
              ]
            ]
          ]
        ]
        "afiliaciones" => array:8 [
          0 => array:3 [
            "entidad" => "Department of Internal Medicine, Faculty of Medicine, Jundishapour University of Medical Sciences, Golestan Hospital, Ahvaz, Khuzestan, Iran, "
            "etiqueta" => "<span class="elsevierStyleSup">a</span>"
            "identificador" => "affa"
          ]
          1 => array:3 [
            "entidad" => "Department of Internal Medicine, Faculty of medicine, Jundishapour university of medical sciences, Ahvaz, Ira, Golestan Hospital, Ahvaz, Khuzestan, Irán, "
            "etiqueta" => "<span class="elsevierStyleSup">b</span>"
            "identificador" => "affb"
          ]
          2 => array:3 [
            "entidad" => "Department of Rheumatology, Faculty of Medicine, Jundishapur University of Medical Sciences, Golestan Hospital, Ahvaz, Khuzestan, Iran, "
            "etiqueta" => "<span class="elsevierStyleSup">c</span>"
            "identificador" => "affc"
          ]
          3 => array:3 [
            "entidad" => " Department of Rheumatology, Faculty of Medicine, Jundishapur University of Medical Sciences, Golestan Hospital, Ahvaz, Khuzestan, Irán, "
            "etiqueta" => "<span class="elsevierStyleSup">d</span>"
            "identificador" => "affd"
          ]
          4 => array:3 [
            "entidad" => "Department of Internal Medicine, Faculty of Medicine, Jundishapur University of Medical Sciences, Iman Hospital, Ahvaz, Khuzestan, Iran, "
            "etiqueta" => "<span class="elsevierStyleSup">e</span>"
            "identificador" => "affe"
          ]
          5 => array:3 [
            "entidad" => " Department of Internal Medicine, Faculty of Medicine, Jundishapur University of Medical Sciences, Iman Hospital, Ahvaz, Khuzestan, Irán, "
            "etiqueta" => "<span class="elsevierStyleSup">f</span>"
            "identificador" => "afff"
          ]
          6 => array:3 [
            "entidad" => "Department of Internal Medicine, Naft Hospital, Ahvaz, Khuzestan, Iran, "
            "etiqueta" => "<span class="elsevierStyleSup">g</span>"
            "identificador" => "affg"
          ]
          7 => array:3 [
            "entidad" => " Department of Internal Medicine, Naft Hospital, Ahvaz, Khuzestan, Irán, "
            "etiqueta" => "<span class="elsevierStyleSup">h</span>"
            "identificador" => "affh"
          ]
        ]
      ]
    ]
    "titulosAlternativos" => array:1 [
      "en" => array:1 [
        "titulo" => "The effect of pentoxifylline on reduction of proteinuria among patients with type 2 diabetes under blockade of angiotensin system&#58; a double blind and randomized clinical trial"
      ]
    ]
    "pdfFichero" => "P1-E544-S3760-A11242.pdf"
    "tienePdf" => true
    "PalabrasClave" => array:2 [
      "es" => array:3 [
        0 => array:4 [
          "clase" => "keyword"
          "titulo" => "Palabras clave"
          "identificador" => "xpalclavsec431759"
          "palabras" => array:1 [
            0 => "Pentoxifilina"
          ]
        ]
        1 => array:4 [
          "clase" => "keyword"
          "titulo" => "Palabras clave"
          "identificador" => "xpalclavsec431761"
          "palabras" => array:1 [
            0 => "Pentoxifilina"
          ]
        ]
        2 => array:4 [
          "clase" => "keyword"
          "titulo" => "Palabras clave"
          "identificador" => "xpalclavsec431763"
          "palabras" => array:1 [
            0 => "Nefropat&#237;a diab&#233;tica"
          ]
        ]
      ]
      "en" => array:3 [
        0 => array:4 [
          "clase" => "keyword"
          "titulo" => "Keywords"
          "identificador" => "xpalclavsec431760"
          "palabras" => array:1 [
            0 => "Proteinuria"
          ]
        ]
        1 => array:4 [
          "clase" => "keyword"
          "titulo" => "Keywords"
          "identificador" => "xpalclavsec431762"
          "palabras" => array:1 [
            0 => "Pentoxifylline"
          ]
        ]
        2 => array:4 [
          "clase" => "keyword"
          "titulo" => "Keywords"
          "identificador" => "xpalclavsec431764"
          "palabras" => array:1 [
            0 => "Diabetic Nephropathy"
          ]
        ]
      ]
    ]
    "tieneResumen" => true
    "resumen" => array:2 [
      "es" => array:1 [
        "resumen" => "<p class="elsevierStylePara">Aunque el bloqueo del sistema renina-angiotensina ha sido citado como el tratamiento inicial para la nefropat&#237;a diab&#233;tica &#40;ND&#41;&#44; en un n&#250;mero significativo de pacientes el avance de la enfermedad renal no se ve frenado en su totalidad por estos agentes&#46; Hemos realizado un ensayo cl&#237;nico doble ciego para valorar el efecto acumulativo de la pentoxifilina &#40;PTX&#41; en la reducci&#243;n de la proteinuria en pacientes con diabetes tipo 2 &#40;DM2&#41; con bloqueo del sistema de angiotensina&#46; La dosis de PTX utilizada en nuestro ensayo fue una cantidad baja de 400 mg diarios y&#44; en nuestra experiencia&#44; no logramos encontrar ning&#250;n art&#237;culo que evaluara el efecto antiprotein&#250;rico de la PTX con esta dosis&#46; De forma aleatoria&#44; se dividieron en dos grupos 100 pacientes con ND y proteinuria persistente a pesar del tratamiento con losart&#225;n y enalapril durante al menos tres meses antes de ser incluidos en el estudio&#46; El grupo de control &#40;n &#61; 50&#44; 26 hombres y 24 mujeres&#41; fueron tratados con losart&#225;n y enalapril&#44; mientras que el grupo de tratamiento &#40;grupo de PTX&#58; n &#61; 50&#44; 28 hombres y 22 mujeres&#41; recibieron losart&#225;n&#44; enalapril y 400 mg&#47;d&#237;a de pentoxifilina durante 6 meses&#46; Al comienzo del estudio no se encontraron diferencias significativas en las caracter&#237;sticas demogr&#225;ficas y cl&#237;nicas de los pacientes&#44; incluida la creatinina s&#233;rica&#44; HbA<span class="elsevierStyleInf">1c</span>&#44; presi&#243;n arterial y excreci&#243;n urinaria de prote&#237;nas entre los dos grupos &#40;p &#62; 0&#44;05&#41;&#46; En el grupo de PTX&#44; la tasa media de excreci&#243;n urinaria de prote&#237;na ha disminuido significativamente de 616&#44;66 a 378&#44;24 mg tras 3 meses &#40;p &#61; 0&#44;000&#41; y a 192&#44;05 mg tras 6 meses &#40;p &#61; 0&#44;000&#41;&#44; mientras que en el grupo de control no se han observado cambios significativos&#46; El beneficioso efecto antiprotein&#250;rico del PTX no estuvo asociado a la intensidad del cambio metab&#243;lico ni a la reducci&#243;n de la presi&#243;n arterial&#46; Adem&#225;s&#44; al final del estudio&#44; el aclaramiento medio de creatinina fue significativamente m&#225;s elevado en el grupo de PTX &#40;p &#61; 0&#44;04&#41;&#46; En conclusi&#243;n&#44; la PTX puede aportar en gran medida un efecto antiprotein&#250;rico acumulativo y ralentizar el grado de filtraci&#243;n glomerular en pacientes con DM2 con bloqueo del sistema de angiotensina&#46;</p>"
      ]
      "en" => array:1 [
        "resumen" => "<p class="elsevierStylePara">Although blockade of renin-angiotensin system have been cited as the first line of therapy for the management of diabetic nephropathy &#40;DN&#41;&#44; however in a substantial number of patients&#44; progression of renal disease are not completely halted by these agents&#46; We have conducted a double blinded clinical trial to assess the additive effect of pentoxifylline on reduction of proteinuria among patients with type 2 DM under blockade of angiotensin system&#46; The dosage of PTX used in our trial was at a low dosage of 400mg daily and to our knowledge&#44; we did not found article which evaluated the antiproteinuric effect of pentoxifylline in this dosage&#46; One hundred patients with DN and persistent proteinuria despite treatment with losartan and enalapril in at least 3 months before inclusion in the study were randomly assigned to two groups&#46; Control group &#40;n&#61;50&#44; 26 males and 24 females&#41; received losartan and enalapril&#44; while treatment group &#40;PTX Group&#41; &#40;n&#61;50&#44; 28 males and 22 females&#41; was given losartan&#44; enalapril and pentoxifylline 400mg&#47;day for 6 months&#46; At the beginning of the study there were no significant differences in demographic and clinical characteristics of patients including serum creatinine&#44; HbA1c&#44; blood pressure and urinary protein excretion between two groups &#40;P&#62;&#46;05&#41;&#46; In the PTX group&#44; the mean rate of urinary protein excretion have significantly decreased from 616&#46;66mg to 378&#46;24 after 3 months &#40;P&#61;&#46;000&#41; and to 192&#46;05mg after 6 months &#40;P&#61;&#46;000&#41; whereas no significant changes were observed in the control group&#46; The beneficial antiproteinuric effect of PTX was not associated to the degree of metabolic control and a reduction of blood pressure&#46; In addition&#44; at the end of study&#44; the mean clearance of creatinine was significantly higher in PTX group &#40;P&#61;&#46;04&#41;&#46; In conclusion&#44; PTX can significantly provide additive antiproteinuric effect and slow the decrease in GFR among patients with type 2 DM under blockade of angiotensin system&#46;</p>"
      ]
    ]
    "bibliografia" => array:2 [
      "titulo" => "Bibliograf&#237;a"
      "seccion" => array:1 [
        0 => array:1 [
          "bibliografiaReferencia" => array:43 [
            0 => array:3 [
              "identificador" => "bib1"
              "etiqueta" => "1"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "K/DOQI clinical practice guidelines and clinical practice recommendations for diabetes and chronic kidney disease. Am J Kidney Dis 2007;49(2 Suppl 2):S12. <a href="http://www.ncbi.nlm.nih.gov/pubmed/17276798" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            1 => array:3 [
              "identificador" => "bib2"
              "etiqueta" => "2"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "National Institutes of Health. Excerpts from United States Renal Data System 2000 Annual Data Report: atlas of end-stage renal disease in the United States: economic costs of ESRD. Am J Kidney Dis 2000;36:163-76."
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            2 => array:3 [
              "identificador" => "bib3"
              "etiqueta" => "3"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Gross JL, de Azevedo MJ, Silveiro SP, Canani LH,\u{A0}Caramori ML,\u{A0}Zelmanovitz T. Diabetic nephropathy: diagnosis, prevention, and treatment. Diabetes Care 2005;28:164-76. <a href="http://www.ncbi.nlm.nih.gov/pubmed/15616252" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            3 => array:3 [
              "identificador" => "bib4"
              "etiqueta" => "4"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Adler AI, Stevens RJ, Manley SE, Bilous RW,\u{A0}Cull CA,\u{A0}Holman RR;\u{A0}UKPDS GROUP. Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney Int 2003;63:225-32. <a href="http://www.ncbi.nlm.nih.gov/pubmed/12472787" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            4 => array:3 [
              "identificador" => "bib5"
              "etiqueta" => "5"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Estacio RO, Jeffers BW, Hiatf WR, Biggerstall SL, Gifford N, Schrier RW. The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non ¿ insulin ¿ dependent diabetes and hypertension. N Engl J Med 1998;338:645-52. <a href="http://www.ncbi.nlm.nih.gov/pubmed/9486993" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            5 => array:3 [
              "identificador" => "bib6"
              "etiqueta" => "6"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Hovind P, Rossing P, Tarnow L, Smidt UM, Parving HH. Progression of diabetic nephropathy. Kidney Int 2001;59:702-9. <a href="http://www.ncbi.nlm.nih.gov/pubmed/11168952" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            6 => array:3 [
              "identificador" => "bib7"
              "etiqueta" => "7"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Parving HH, Hommel E, Jensen BR, Hansen HP. Long-term beneficial effect of ACE inhibition on diabetic nephropathy in normotensive type 1 diabetic patients. Kidney Int 2001;60:228-34. <a href="http://www.ncbi.nlm.nih.gov/pubmed/11422755" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            7 => array:3 [
              "identificador" => "bib8"
              "etiqueta" => "8"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Lewis EJ, Hunsicker LG, Clarke WR, Berl T,\u{A0}Pohl MA,\u{A0}Lewis JB,\u{A0}et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001;345:851-60. <a href="http://www.ncbi.nlm.nih.gov/pubmed/11565517" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            8 => array:3 [
              "identificador" => "bib9"
              "etiqueta" => "9"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Brenner BM, Cooper ME, de Zeeuw D, Keane WF,\u{A0}Mitch WE,\u{A0}Parving HH,\u{A0}et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001;345:861-9. <a href="http://www.ncbi.nlm.nih.gov/pubmed/11565518" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            9 => array:3 [
              "identificador" => "bib10"
              "etiqueta" => "10"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Lewis E, Hunsicker L, Bain R, Rohde R. The\u{A0} effect\u{A0} of angiotensin converting enzyme inhibition on diabetic nephropathy. N Engl J Med 1993;329:1456-62. <a href="http://www.ncbi.nlm.nih.gov/pubmed/8413456" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            10 => array:3 [
              "identificador" => "bib11"
              "etiqueta" => "11"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "de Zeeuw D, Remuzzi G, Parving HH, Keane WF,\u{A0}Zhang Z,\u{A0}Shahinfar S,\u{A0}et al. Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL. Kidney Int 2004;65:2309-20. <a href="http://www.ncbi.nlm.nih.gov/pubmed/15149345" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            11 => array:3 [
              "identificador" => "bib12"
              "etiqueta" => "12"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Jafar TH, Stark PC, Schmid CH, Landa M,\u{A0}Maschio G,\u{A0}Marcantoni C, et al.;\u{A0}AIPRD Study Group. Angiotensin-Converting Enzymne Inhibition and Progression of Renal Diseaseet al. Proteinuria as a modifiable risk factor for the progression of non-diabetic renal disease. Kidney Int 2001;60:1131-40. <a href="http://www.ncbi.nlm.nih.gov/pubmed/11532109" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            12 => array:3 [
              "identificador" => "bib13"
              "etiqueta" => "13"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "ADVANCE Collaborative Group, Patel A, MacMahon S, Chalmers J,\u{A0}Neal B,\u{A0}Billot L,\u{A0}et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008;358:2560-72. <a href="http://www.ncbi.nlm.nih.gov/pubmed/18539916" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            13 => array:3 [
              "identificador" => "bib14"
              "etiqueta" => "14"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Basi S, Lewis JB. Microalbuminuria as a target to improve cardiovascular and renal outcomes. Am J Kidney Dis 2006;47:927-46. <a href="http://www.ncbi.nlm.nih.gov/pubmed/16731288" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:1 [
                        "itemHostRev" => array:3 [
                          "pii" => "S0140673606692519"
                          "estado" => "S300"
                          "issn" => "01406736"
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            14 => array:3 [
              "identificador" => "bib15"
              "etiqueta" => "15"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Fliser D, Wagner KK, Loos A, Tsikas D,\u{A0}Haller H.\u{A0}Chronic angiotensin II receptor blockade reduces (intra)renal vascular resistance in patients with type 2 diabetes. J Am Soc Nephrol 2005;16:1135-40. <a href="http://www.ncbi.nlm.nih.gov/pubmed/15716329" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            15 => array:3 [
              "identificador" => "bib16"
              "etiqueta" => "16"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Hilgers KF, Veelken R. Type 2 diabetic nephropathy: never too early to treat? J Am Soc Nephrol 2005;16:574-5. <a href="http://www.ncbi.nlm.nih.gov/pubmed/15703269" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            16 => array:3 [
              "identificador" => "bib17"
              "etiqueta" => "17"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Nagai Y, Yao L, Kobori H, Miyata K,\u{A0}Ozawa Y,\u{A0}Miyatake A,\u{A0}et al. Temporary angiotensin II blockade at the prediabetic stage attenuates the development of renal injury in type 2 diabetic rats. J Am Soc Nephrol 2005;16:703-11. <a href="http://www.ncbi.nlm.nih.gov/pubmed/15647337" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            17 => array:3 [
              "identificador" => "bib18"
              "etiqueta" => "18"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Vasylyeva TL, Chen X, Ferry RJ Jr. Insulin-like growth factor binding protein-3 mediates cytokine-induced mesangial cell apoptosis. Growth Horm IGF Res 2005;15:207-14. <a href="http://www.ncbi.nlm.nih.gov/pubmed/15935983" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            18 => array:3 [
              "identificador" => "bib19"
              "etiqueta" => "19"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Lin CL, Wang JY, Huang YT, Kuo YH,\u{A0}Surendran K,\u{A0}Wang FS. Wnt/beta-catenin signaling modulates survival of high glucose-stressed mesangial cells. J Am Soc Nephrol 2006;17:2812-20. <a href="http://www.ncbi.nlm.nih.gov/pubmed/16943306" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            19 => array:3 [
              "identificador" => "bib20"
              "etiqueta" => "20"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Maxhimer JB, Somenek M, Rao G, Pesce CE,\u{A0}Baldwin D Jr,\u{A0}Gattuso P,\u{A0}et al. Heparanase-1 gene expression and regulation by high glucose in renal epithelial cells: a potential role in the pathogenesis of proteinuria in diabetic patients. Diabetes 2005;54:2172-8. <a href="http://www.ncbi.nlm.nih.gov/pubmed/15983219" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            20 => array:3 [
              "identificador" => "bib21"
              "etiqueta" => "21"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "van den Hoven MJ, Rops AL, Bakker MA, Aten J,\u{A0}Rutjes N,\u{A0}Roestenberg P,\u{A0}et al. Increased expression of heparanase in overt diabetic nephropathy. Kidney Int 2006;70:2100-8. <a href="http://www.ncbi.nlm.nih.gov/pubmed/17051139" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            21 => array:3 [
              "identificador" => "bib22"
              "etiqueta" => "22"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Nguyen G. Renin/prorenin receptors. Kidney Int 2006;69:1503-9."
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            22 => array:3 [
              "identificador" => "bib23"
              "etiqueta" => "23"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Ichihara A, Suzuki F, Nakagawa T, Kaneshiro Y,\u{A0}Takemitsu T,\u{A0}Sakoda M,\u{A0}et al. Prorenin receptor blockade inhibits development of glomerulosclerosis in diabetic angiotensin II type 1a receptor-deficient mice. J Am Soc Nephrol 2006;17:1950-61. <a href="http://www.ncbi.nlm.nih.gov/pubmed/16738017" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            23 => array:3 [
              "identificador" => "bib24"
              "etiqueta" => "24"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Hohenstein B, Hausknecht B, Boehmer K, Riess R,\u{A0}Brekken RA,\u{A0}Hugo CP. Local VEGF activity but not VEGF expression is tightly regulated during diabetic nephropathy in man. Kidney Int 2006;69:1654-61. <a href="http://www.ncbi.nlm.nih.gov/pubmed/16541023" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            24 => array:3 [
              "identificador" => "bib25"
              "etiqueta" => "25"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "de Vriese AS, Tilton RG, Elger M, \u{A0}Stephan CC,\u{A0}Kriz W,\u{A0}Lameire NH. Antibodies against vascular endothelial growth factor improve early renal dysfunction in experimental diabetes. J Am Soc Nephrol 2001;12:993-1000. <a href="http://www.ncbi.nlm.nih.gov/pubmed/11316858" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            25 => array:3 [
              "identificador" => "bib26"
              "etiqueta" => "26"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Hayashida T, Schnaper HW. High ambient glucose enhances sensitivity to TGF-beta1 via extracellular signal--regulated kinase and protein kinase Cdelta activities in human mesangial cells. J Am Soc Nephrol 2004;15:2032-41. <a href="http://www.ncbi.nlm.nih.gov/pubmed/15284289" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            26 => array:3 [
              "identificador" => "bib27"
              "etiqueta" => "27"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Festa A, D¿Agostino R Jr, Howard G, Mykkanen L, Tracy R, Haffner S. Inflammation and microalbuminuria in nondiabetic and type 2 diabetic subjects: The Insulin Resistance Atherosclerosis Study. Kidney Int 2000;58:1703-10. <a href="http://www.ncbi.nlm.nih.gov/pubmed/11012904" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            27 => array:3 [
              "identificador" => "bib28"
              "etiqueta" => "28"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Navarro JF, Mora C, Macía M, García J. Inflammatory parameters are independently associated with urinary albumin excretion in type 2 diabetes mellitus. Am J Kidney Dis 2003;42:53-61. <a href="http://www.ncbi.nlm.nih.gov/pubmed/12830456" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            28 => array:3 [
              "identificador" => "bib29"
              "etiqueta" => "29"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Navarro J. Diabetic nephropathy: A matter of inflammation? Nefrologia 2003;23:381-9. <a href="http://www.ncbi.nlm.nih.gov/pubmed/14658163" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            29 => array:3 [
              "identificador" => "bib30"
              "etiqueta" => "30"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "30.Gruden G, Setti G, Hayward A, Sugden D,\u{A0}Duggan S,\u{A0}Burt D,\u{A0}et al. Mechanical stretch induces monocyte chemoattractant activity via an NF-kappaB-dependent monocyte chemoattractant protein-1-mediated pathway in human mesangial cells: inhibition by rosiglitazone. J Am Soc Nephrol 2005;16:688-96. <a href="http://www.ncbi.nlm.nih.gov/pubmed/15677312" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            30 => array:3 [
              "identificador" => "bib31"
              "etiqueta" => "31"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Akahori H, Ota T, Torita M, Ando H,\u{A0}Kaneko S,\u{A0}Takamura T. Tranilast prevents the progression of experimental diabetic nephropathy through suppression of enhanced extracellular matrix gene expression. J Pharmacol Exp Ther 2005;314:514-21. <a href="http://www.ncbi.nlm.nih.gov/pubmed/15857946" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            31 => array:3 [
              "identificador" => "bib32"
              "etiqueta" => "32"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Soma J, Sato K, Saito H, Tsuchiya Y. Effect of tranilast in early-stage diabetic nephropathy. Nephrol Dial Transplant 2006;21:2795-9. <a href="http://www.ncbi.nlm.nih.gov/pubmed/16820373" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            32 => array:3 [
              "identificador" => "bib33"
              "etiqueta" => "33"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Soma J, Sugawara T, Huang YD,\u{A0}Nakajima J, Kawamura M. Tranilast slows the progression of advanced diabetic nephropathy. Nephron 2002;92:693-8. <a href="http://www.ncbi.nlm.nih.gov/pubmed/12372957" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            33 => array:3 [
              "identificador" => "bib34"
              "etiqueta" => "34"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "34.\u{A0}Abdollahi M,\u{A0}Chan TS,\u{A0}Subrahmanyam V,\u{A0}O'Brien PJ. Effects of phosphodiesterase 3, 4, 5 inhibitors on hepatocyte cAMP levels, glycogenolysis, gluconeogenesis and susceptibility to a mitochondrial toxin. Mol Cell Biochem 2003;252:205-11. <a href="http://www.ncbi.nlm.nih.gov/pubmed/14577594" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            34 => array:3 [
              "identificador" => "bib35"
              "etiqueta" => "35"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "35.\u{A0}Noyan T,\u{A0}Onem O,\u{A0}Ramazan Sekeroglu M,\u{A0}Koseoglu B,\u{A0}Dulger H,\u{A0}Bayram I, et al. Effects of erythropoietin and pentoxifylline on the oxidant and antioxidant systems in the experimental short bowel syndrome. Cell Biochem Funct 2003;21:49-54. <a href="http://www.ncbi.nlm.nih.gov/pubmed/12579521" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            35 => array:3 [
              "identificador" => "bib36"
              "etiqueta" => "36"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Navarro J, Mora C, Muros M, Macía M, García J. Effects of pentoxifylline administration on urinary N-acetyl-beta-glucosaminidase excretion in type 2 diabetic patients: A short-term, prospective, randomised study. Am J Kidney Dis 2003;42:264-70. <a href="http://www.ncbi.nlm.nih.gov/pubmed/12900807" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            36 => array:3 [
              "identificador" => "bib37"
              "etiqueta" => "37"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "37.\u{A0}Navarro JF, Mora-Fernández C. The role of TNF-alpha in diabetic nephropathy: Pathogenic and therapeutic implications. Cytokine Growth Factor Rev 2006;17:441-50. <a href="http://www.ncbi.nlm.nih.gov/pubmed/17113815" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            37 => array:3 [
              "identificador" => "bib38"
              "etiqueta" => "38"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Navarro J, Mora C, Muros M, Macía M, García J. Additive antiproteinuric effect of pentoxifylline in patients with type 2 diabetes under angiotensin II receptor blockade: A short-term, randomized, controlled trial. J Am Soc Nephrol 2005;16:2119-26. <a href="http://www.ncbi.nlm.nih.gov/pubmed/15917336" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            38 => array:3 [
              "identificador" => "bib39"
              "etiqueta" => "39"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Harmankaya O, Seber S, Yilmaz M. Combination of pentoxifylline with angiotensin converting enzyme inhibitors produces an additional reduction in microalbuminuria in hypertensive type 2 diabetic patients. Ren Fail 2003;25:465-70. <a href="http://www.ncbi.nlm.nih.gov/pubmed/12803510" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            39 => array:3 [
              "identificador" => "bib40"
              "etiqueta" => "40"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Diskin CJ, Stokes TJ, Dansby LM, Radcliff L, Carter TB. Will the addition of pentoxifylline reduce proteinuria in patients with diabetic glomerulosclerosis refractory to maximal doses of both an angiotensin-converting enzyme inhibitor and an angiotensin receptor blocker? J Nephrol 2007;20:410-6. <a href="http://www.ncbi.nlm.nih.gov/pubmed/17879206" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            40 => array:3 [
              "identificador" => "bib41"
              "etiqueta" => "41"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Aminorroaya A, Janghorbani M, Rezvanian H, Aminian T, Gharavi M, Amini M. Comparison of the effect of pentoxifylline and captopril on proteinuria in patients with type 2 diabetes mellitus. Nephron Clin Pract 2005;99:c73-7. <a href="http://www.ncbi.nlm.nih.gov/pubmed/15665549" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            41 => array:3 [
              "identificador" => "bib42"
              "etiqueta" => "42"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Rodríguez-Morán M, Guerrero-Romero F. Pentoxifylline is as effective as captopril in the reduction of microalbuminuria in non-hypertensive type 2 diabetic patients--a randomized, equivalent trial. Clin Nephrol 2005;64:91-7. <a href="http://www.ncbi.nlm.nih.gov/pubmed/16114784" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            42 => array:3 [
              "identificador" => "bib43"
              "etiqueta" => "43"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "43.\u{A0}Perkins RM, Aboudara MC, Uy AL, Olson SW, Cushner HM, Yuan CM. Effect of pentoxifylline on GFR decline in CKD: a pilot, double-blind, randomized, placebo-controlled trial. Am J Kidney Dis 2009;53:606-16. <a href="http://www.ncbi.nlm.nih.gov/pubmed/19216016" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
          ]
        ]
      ]
    ]
  ]
  "idiomaDefecto" => "es"
  "url" => "/02116995/0000003200000006/v0_201502091338/X0211699512002267/v0_201502091339/es/main.assets"
  "Apartado" => array:4 [
    "identificador" => "35393"
    "tipo" => "SECCION"
    "es" => array:2 [
      "titulo" => "Artículos Originales"
      "idiomaDefecto" => true
    ]
    "idiomaDefecto" => "es"
  ]
  "PDF" => "https://static.elsevier.es/multimedia/02116995/0000003200000006/v0_201502091338/X0211699512002267/v0_201502091339/es/P1-E544-S3760-A11242.pdf?idApp=UINPBA000064&text.app=https://revistanefrologia.com/"
  "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X0211699512002267?idApp=UINPBA000064"
]
Información del artículo
ISSN: 02116995
Idioma original: Español
Datos actualizados diariamente
año/Mes Html Pdf Total
2024 Noviembre 10 4 14
2024 Octubre 85 62 147
2024 Septiembre 66 34 100
2024 Agosto 85 85 170
2024 Julio 118 59 177
2024 Junio 80 72 152
2024 Mayo 86 56 142
2024 Abril 87 83 170
2024 Marzo 62 44 106
2024 Febrero 70 50 120
2024 Enero 85 28 113
2023 Diciembre 50 41 91
2023 Noviembre 77 42 119
2023 Octubre 117 54 171
2023 Septiembre 120 42 162
2023 Agosto 107 36 143
2023 Julio 143 52 195
2023 Junio 119 47 166
2023 Mayo 100 69 169
2023 Abril 82 48 130
2023 Marzo 112 47 159
2023 Febrero 50 49 99
2023 Enero 88 56 144
2022 Diciembre 84 55 139
2022 Noviembre 110 161 271
2022 Octubre 97 70 167
2022 Septiembre 85 52 137
2022 Agosto 104 73 177
2022 Julio 130 87 217
2022 Junio 120 63 183
2022 Mayo 102 65 167
2022 Abril 148 65 213
2022 Marzo 122 73 195
2022 Febrero 88 79 167
2022 Enero 66 41 107
2021 Diciembre 76 54 130
2021 Noviembre 109 57 166
2021 Octubre 93 85 178
2021 Septiembre 81 60 141
2021 Agosto 106 72 178
2021 Julio 57 31 88
2021 Junio 63 43 106
2021 Mayo 56 52 108
2021 Abril 144 145 289
2021 Marzo 107 43 150
2021 Febrero 88 32 120
2021 Enero 91 54 145
2020 Diciembre 83 28 111
2020 Noviembre 74 35 109
2020 Octubre 76 35 111
2020 Septiembre 97 25 122
2020 Agosto 94 36 130
2020 Julio 129 36 165
2020 Junio 123 18 141
2020 Mayo 139 39 178
2020 Abril 115 49 164
2020 Marzo 154 43 197
2020 Febrero 145 60 205
2020 Enero 220 59 279
2019 Diciembre 115 62 177
2019 Noviembre 118 91 209
2019 Octubre 51 73 124
2019 Septiembre 52 69 121
2019 Agosto 41 62 103
2019 Julio 399 50 449
2019 Junio 354 65 419
2019 Mayo 73 50 123
2019 Abril 288 47 335
2019 Marzo 288 32 320
2019 Febrero 163 28 191
2019 Enero 170 32 202
2018 Diciembre 198 55 253
2018 Noviembre 280 29 309
2018 Octubre 263 18 281
2018 Septiembre 303 39 342
2018 Agosto 225 20 245
2018 Julio 180 28 208
2018 Junio 154 28 182
2018 Mayo 121 16 137
2018 Abril 118 18 136
2018 Marzo 90 9 99
2018 Febrero 76 15 91
2018 Enero 101 9 110
2017 Diciembre 94 10 104
2017 Noviembre 77 17 94
2017 Octubre 100 19 119
2017 Septiembre 68 13 81
2017 Agosto 62 12 74
2017 Julio 56 7 63
2017 Junio 66 15 81
2017 Mayo 79 19 98
2017 Abril 61 14 75
2017 Marzo 61 13 74
2017 Febrero 49 11 60
2017 Enero 79 16 95
2016 Diciembre 102 9 111
2016 Noviembre 141 17 158
2016 Octubre 174 18 192
2016 Septiembre 215 10 225
2016 Agosto 264 4 268
2016 Julio 284 14 298
2016 Junio 192 0 192
2016 Mayo 189 0 189
2016 Abril 146 0 146
2016 Marzo 104 0 104
2016 Febrero 146 0 146
2016 Enero 133 0 133
2015 Diciembre 194 0 194
2015 Noviembre 133 0 133
2015 Octubre 178 0 178
2015 Septiembre 145 0 145
2015 Agosto 106 0 106
2015 Julio 125 0 125
2015 Junio 87 0 87
2015 Mayo 138 0 138
2015 Abril 33 0 33
2015 Febrero 2171 0 2171
Mostrar todo

Siga este enlace para acceder al texto completo del artículo

Idiomas
Nefrología
es en

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?